[Drug therapy for prevention of falls and fractures].
The primary goal in the practical management of osteoporosis is to prevent first or subsequent fractures and thereby to avoid acute or chronic pain and progressive skeletal deformity. Therapeutic strategies should always take the complex pathogenetic mechanisms of fractures into account, especially the fact that mechanical impacts and falls play an important role in the majority of fracture events. Accordingly, recommendations to patients and the selection of drugs should aim at both, falls and fractures. In this context there is an increasing interest in the dual effects of vitamin D on bone and muscle. Controlled studies proved that adequate vitamin D supplementation is able to improve muscle strength, coordination and body sway and thereby reduce the risk of falls and fractures. Alendronate has been studied extensively by large trials of high quality and its efficacy to reduce the risk of vertebral and nonvertebral fractures is in line with the criteria of evidence-based medicine. The innovative combination of 70 mg alendronate with 2,800 IU vitamin D in a once-weekly tablet guarantees a basic supply with this important prohormone for bone and muscle. Due to a regular combined intake an improved compliance can be anticipated which will be followed by better therapeutic results in osteoporosis patients with increased fracture risk.
Ringe
Johann D
JD
Medizinische Klinik 4 (Schwerpunkt Rheumatologie/Osteologie), Klinikum Leverkusen, Akademisches Lehrkrankenhaus der Universität zu Köln, Leverkusen, Germany. ringe@klinikum-lev.de
D000058:Accidental Falls / Q000517:prevention & control*; D019386:Alendronate / Q000008:administration & dosage / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D050723:Fractures, Bone / Q000517:prevention & control*; D005598:Fractures, Spontaneous / Q000517:prevention & control; D006801:Humans; D053580:Muscle Strength; D010018:Osteomalacia / Q000517:prevention & control; D010024:Osteoporosis / Q000188:drug therapy*; D010349:Patient Compliance; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D040242:Risk Reduction Behavior; D016103:Spinal Fractures / Q000517:prevention & control*; D014807:Vitamin D / Q000008:administration & dosage / Q000627:therapeutic use*
D050071:Bone Density Conservation Agents; D014807:Vitamin D; D019386:Alendronate